08/09/2017
NCCN has published updates to the NCCN Guidelines® and the NCCN Compendium® for Myeloproliferative Neoplasms
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Myeloproliferative Neoplasms. These NCCN Guidelines® are currently available as Version 1.2018.
- Myelofibrosis
- Hydroxyurea was added as an option for low-risk symptomatic myelofibrosis if cytoreduction would be symptomatically beneficial (MF-1).
- Pomalidomide ± prednisone (category 3) was added as an option for the management of MF-associated anemia in patients with serum erythropoietin (EPO) ≥500 mU/mL. (MF-4)
- New algorithms were included for the management of the following subtypes:
- Polycythemia Vera (PV-1)
- Essential Thrombocythemia (ET-1)